Epigeneron, Inc. and Brain Research Institute, Niigata University started joint research on novel drug target discovery research for neurodegenerative diseases

28 Feb 2022

Epigeneron announced that it has entered into a joint research agreement with Brain Research Institute, Niigata University (Akiyoshi Kakita, M.D., Ph.D., Professor, Department of Pathology, Brain Research Institute, Niigata University) on drug target discovery research with a view to create new therapeutic medicines for rare neurodegenerative diseases.

Under this collaboration, Kakita laboratory, Brain Research Institute, Niigata University and Epigeneron will jointly conduct multi-omics analysis by using the locus specific chromatin Immunoprecipitation (ChIP) for brain samples. Based on the results of the analysis, Epigeneron and Kakita laboratory will identify biomolecules involved in the control of the causative gene of rare neurodegenerative diseases and aim to create new therapeutic medicine.

About Department of Pathology, Brain Research Institute, Niigata University:
To provide the highest quality pathology services and scientific evidence focused on the advancement of developments in the field of neuropathology.
As an academic pathology department, we aim to deliver a high degree of professionalism in clinicopathological diagnostic services and neuropathology research, utilizing comprehensive and innovative approaches and building departmental competence to meet the needs of patients, institutions, and society.
Our approach will involve taking full advantage of opportunities to advance both the science and practice of neuropathology through individual and collaborative research, which hopefully will produce leading practitioners and researchers.

For more details, please refer the link below;
Department of Pathology, Brain Research Institute, Niigata University: https://pathology-bri-niigata-u.jp/en/

About Epigeneron
The regulation of gene expression, which includes epigenetic mechanisms, is a growing research area for industrial and academic interests in discovering novel drug targets.

Epigeneron was founded by Hodaka Fujii, MD, PhD and Toshitsugu Fujita, PhD to translate their innovative inventions, locus-specific ChIP and ORNi-PCR, into the industrial applications such as exploitation and identification of revolutionary drug targets and detection of rare gene sequences in biological specimens. It pioneers revolutionary drug discovery based on epigenetic and other mechanisms of gene expression regulation with its proprietary technologies and accumulated knowledge. Epigeneron is actively promoting business partnerships with companies in the pharmaceutical, diagnostic, and other industrial areas enabling them to achieve extensive innovation in drug discovery, diagnostics, and other molecular testing.

For inquiry:Administration and accounting, Epigeneron, Inc.
Phone: 03-6661-2764
E-mail: info@epigeneron.com